Heron Therapeutics (NASDAQ:HRTX – Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.
Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Heron Therapeutics Price Performance
Shares of NASDAQ HRTX opened at $2.24 on Tuesday. Heron Therapeutics has a one year low of $1.04 and a one year high of $3.93. The firm’s 50 day simple moving average is $1.70 and its two-hundred day simple moving average is $1.71. The stock has a market capitalization of $340.69 million, a P/E ratio of -12.44 and a beta of 1.60.
Analyst Ratings Changes
About Heron Therapeutics
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- What Are the U.K. Market Holidays? How to Invest and Trade
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- How to Use the MarketBeat Stock Screener
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
